Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

theBigDollarski Jul. 24 at 3:42 PM

$NKTX nabbed a couple thousand at 2.25....this stock is too easy

0 · Reply

metalcook Jul. 24 at 3:27 PM

$ACET so market thinks results are a 0 and management is a 0 as they will burn the cash instead of a reorganization. Looks a lot like $NKTX

0 · Reply

youbi336 Jul. 17 at 1:22 AM

$NKTX

1 · Reply

Lukey63 Jul. 16 at 8:10 PM

$NKTX Looking at the chart 2.38 - 2.60 seems like a good buy range.

0 · Reply

Gmebe Jul. 13 at 8:19 PM

$NKTX just bought back in. Rinse and repeat yet again.

1 · Reply

GLPHOTOX Jul. 13 at 5:34 PM

$NKTX Everything is a sea of red today

0 · Reply

RaySan Jul. 10 at 2:06 PM

$NKTX Added

0 · Reply

Lukey63 Jul. 10 at 1:46 PM

$NKTX Every single time it looks like it will break out it pukes. Really makes me wonder what is going on with trading. Fown $0.7 in two days? Yes it was up strongly in a short period but it only got to cash value. The price action is very fishy.

1 · Reply

pleiades108 Jul. 10 at 1:14 PM

$NKTX Unfortunately, the price structure since March 2025 has been very corrective looking, and that can only mean one thing 🚨, more likely than not. 🔪

0 · Reply

vu_jade Jul. 9 at 7:24 PM

$NKTX buy the dip Technical look bullish

2 · Reply

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Jun 30, 2026, 2:00 PM EDT - 25 days ago

Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 26, 2026, 8:45 AM EDT - 4 weeks ago

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

2026-06-23T11:33:17.000Z - 4 weeks ago

Nkarta initiated with a Buy at TD Cowen

Jun 10, 2026, 4:00 PM EDT - 6 weeks ago

Nkarta Transcript: AGM 2026

2026-05-18T12:43:42.000Z - 2 months ago

Nkarta price target lowered to $9 from $25 at Evercore ISI

2026-05-12T22:15:15.000Z - 2 months ago

Nkarta reports Q1 EPS (37c), consensus (37c)

May 12, 2026, 4:01 PM EDT - 2 months ago

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026, 4:00 PM EDT - 2 months ago

Nkarta Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

Nkarta Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

Nkarta Slides: Corporate presentation

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Nkarta Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Nkarta Proxy statement: Proxy filing

2026-04-15T20:05:13.000Z - 3 months ago

Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials

Apr 15, 2026, 4:01 PM EDT - 3 months ago

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Apr 15, 2026, 3:45 PM EDT - 3 months ago

Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 3 months ago

Nkarta to Participate in Needham Virtual Healthcare Conference

2026-03-31T11:08:50.000Z - 4 months ago

Nkarta price target lowered to $12 from $14 at Mizuho

2026-03-26T11:51:19.000Z - 4 months ago

Nkarta price target raised to $11 from $10 at Needham

2026-03-25T21:25:16.000Z - 4 months ago

Nkarta files $350M mixed securities shelf

2026-03-25T20:05:15.000Z - 4 months ago

Nkarta reports Q4 EPS (37c), consensus (29c)

Mar 25, 2026, 4:01 PM EDT - 4 months ago

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Mar 25, 2026, 4:00 PM EDT - 4 months ago

Nkarta Annual report: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 4 months ago

Nkarta Earnings release: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 4 months ago

Nkarta Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 4 months ago

Nkarta Registration statement: Registration filing

Mar 10, 2026, 10:40 AM EDT - 4 months ago

Nkarta Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:10 AM EST - 5 months ago

Nkarta Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 8:00 AM EST - 5 months ago

Nkarta to Participate in March Investor Conferences

Dec 4, 2025, 10:50 AM EST - 8 months ago

Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:09 AM EST - 8 months ago

Nkarta to Participate in Evercore Healthcare Conference

Nov 13, 2025, 5:00 PM EST - 9 months ago

Nkarta Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:40 AM EST - 9 months ago

Nkarta Transcript: Stifel 2025 Healthcare Conference

2025-11-11T12:45:27.000Z - 9 months ago

Nkarta price target lowered to $11 from $12 at Stifel

2025-11-10T21:05:10.000Z - 9 months ago

Nkarta reports Q3 EPS (29c), consensus (30c)

Nov 10, 2025, 4:01 PM EST - 9 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 10, 2025, 4:00 PM EST - 9 months ago

Nkarta Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 9 months ago

Nkarta Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Nkarta Slides: Corporate Presentation

Oct 30, 2025, 1:14 PM EDT - 9 months ago

Nkarta to Participate in November Investor Conferences

Oct 22, 2025, 10:07 AM EDT - 9 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Sep 9, 2025, 8:30 AM EDT - 11 months ago

Nkarta Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:01 AM EDT - 11 months ago

Nkarta to Participate in a September Investor Conference

2025-08-14T11:21:16.000Z - 1 year ago

Nkarta price target lowered to $12 from $14 at Stifel

2025-08-12T20:13:01.000Z - 1 year ago

Nkarta reports Q2 EPS (31c), consensus (35c)

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Nkarta Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Nkarta Earnings release: Q2 2025

Jul 30, 2025, 11:00 AM EDT - 1 year ago

Nkarta Transcript: H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

2025-06-10T10:55:13.000Z - 1 year ago

Nkarta price target lowered to $14 from $16 at Mizuho

2025-06-06T13:00:35.000Z - 1 year ago

Nkarta appoints Shawn Rose as CMO, head of R&D

Jun 6, 2025, 8:52 AM EDT - 1 year ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

2025-05-15T08:51:43.000Z - 1 year ago

Nkarta downgraded to Market Perform from Outperform at William Blair

2025-05-14T20:15:15.000Z - 1 year ago

Nkarta reports Q1 EPS (43c), consensus (45c)

May 14, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Earnings release: Q1 2025

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing

Apr 8, 2025, 11:00 AM EDT - 1 year ago

Nkarta Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in an April Investor Conference

2025-03-27T10:26:21.000Z - 1 year ago

Nkarta price target lowered to $14 from $15 at Stifel

2025-03-26T20:16:10.000Z - 1 year ago

Nkarta announces restructuring and workforce reduction of 34%

2025-03-26T20:10:42.000Z - 1 year ago

Nkarta reports Q4 EPS (35c), consensus (40c)

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Earnings release: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Annual report: Q4 2024

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Nkarta Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Nkarta Transcript: TD Cowen 45th Annual Healthcare Conference

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 4, 2024, 2:10 PM EST - 1 year ago

Nkarta Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Nkarta Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Quarterly report: Q3 2024

Sep 10, 2024, 12:30 PM EDT - 2 years ago

Nkarta Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 4:01 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conference

Aug 13, 2024, 9:03 PM EDT - 2 years ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Nkarta Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Nkarta Earnings release: Q2 2024

Jul 24, 2024, 6:00 AM EDT - 2 years ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 2 years ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 2 years ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 2 years ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 9, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Earnings release: Q1 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 9, 2024, 1:30 PM EDT - 2 years ago

Nkarta Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 5, 2024, 3:35 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 26, 2024, 2:00 PM EDT - 2 years ago

Nkarta Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Slides: Corporate Presentation

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Annual report: Q4 2023

Mar 11, 2024, 12:00 PM EDT - 2 years ago

Nkarta Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Nkarta Transcript: TD Cowen 44th Annual Health Care Conference 2024

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 28, 2023, 12:30 PM EST - 2 years ago

Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Earnings release: Q3 2023

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 3 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 8:00 AM EDT - 3 years ago

Nkarta Transcript: FDA Announcement

Oct 17, 2023, 8:00 AM EDT - 3 years ago

Nkarta Press release: FDA Announcement

Oct 17, 2023, 7:01 AM EDT - 3 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q2 2023

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q2 2023

Aug 10, 2023, 7:01 AM EDT - 3 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 3 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 3 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Transcript: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Press release: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Slides: Study Update

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 3 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 3 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 3 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q1 2023

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

theBigDollarski Jul. 24 at 3:42 PM

$NKTX nabbed a couple thousand at 2.25....this stock is too easy

0 · Reply

metalcook Jul. 24 at 3:27 PM

$ACET so market thinks results are a 0 and management is a 0 as they will burn the cash instead of a reorganization. Looks a lot like $NKTX

0 · Reply

youbi336 Jul. 17 at 1:22 AM

$NKTX

1 · Reply

Lukey63 Jul. 16 at 8:10 PM

$NKTX Looking at the chart 2.38 - 2.60 seems like a good buy range.

0 · Reply

Gmebe Jul. 13 at 8:19 PM

$NKTX just bought back in. Rinse and repeat yet again.

1 · Reply

GLPHOTOX Jul. 13 at 5:34 PM

$NKTX Everything is a sea of red today

0 · Reply

RaySan Jul. 10 at 2:06 PM

$NKTX Added

0 · Reply

Lukey63 Jul. 10 at 1:46 PM

1 · Reply

pleiades108 Jul. 10 at 1:14 PM

$NKTX Unfortunately, the price structure since March 2025 has been very corrective looking, and that can only mean one thing 🚨, more likely than not. 🔪

0 · Reply

vu_jade Jul. 9 at 7:24 PM

$NKTX buy the dip Technical look bullish

2 · Reply

GLPHOTOX Jul. 8 at 8:51 PM

$NKTX let’s keep it going !

0 · Reply

purplesniper Jul. 8 at 8:23 PM

$NKTX

0 · Reply

GLPHOTOX Jul. 7 at 3:43 PM

$NKTX Any chart masters out there ? Where is the next resistance ?

0 · Reply

theBigDollarski Jul. 7 at 2:59 PM

$NKTX do we finally get a breakout??

0 · Reply

Underkat Jul. 6 at 7:46 PM

$NKTX

0 · Reply

purplesniper Jul. 6 at 3:14 PM

$NKTX

0 · Reply

StockScanners Jul. 4 at 5:03 PM

$NKTX keep watch if this holds above 3.10

0 · Reply

topstockalerts Jul. 3 at 1:34 AM

$NKTX this is starting to look like a trend, not just a bounce

0 · Reply

Gmebe Jul. 2 at 6:46 PM

$NKTX nows the time to sell and wait for the discount back to 2.7 or 2.8

0 · Reply

purplesniper Jul. 2 at 5:29 PM

$NKTX volume higher than normal

0 · Reply

youbi336 Jul. 2 at 2:00 AM

$NKTX Come on! Even $FATE which has always lagged behind one whole dollar has caught up and overtook! Time to move!

0 · Reply

Joesh82 Jun. 30 at 12:49 PM

$NKTX H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.

0 · Reply

Market Cap	162.41M
Revenue (ttm)	0.00
Net Income (ttm)	-104.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	699,200
Avg Vol	677,604
Day's Range	N/A - N/A
Shares Out	71.55M
Stochastic %K	6%
Beta	0.90
Analysts	Strong Sell
Price Target	$11.33